Evidence map›Paper›PMID 26929759›Full record

ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2015

Efficacy of microencapsulated lactic acid bacteria in Helicobater pylori eradication therapy.

Maha A Khalil, Mostafa M El-Sheekh, Hala I El-Adawi, Nehal M El-Deeb, Mohamed Z Hussein

Open access · goldAbstract read
In one paragraph

Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Gamma-Aminobutyric Acid-ProducingFoods (Basel, Switzerland) · 2023
    Article
  3. Molecules (Basel, Switzerland) · 2022
    Article
  4. Frontiers in microbiology · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Frontiers in microbiology · 2018
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Maha A KhalilDepartment of Botany, Faculty of Science, Tanta University, Tanta, Egypt; Department of Biology, Faculty of Science, Taif University, Taif, KSA.
Mostafa M El-SheekhDepartment of Botany, Faculty of Science, Tanta University, Tanta, Egypt.
Hala I El-AdawiDepartment of Medical Biotechnology, Genetic Engineering and Biotech Institute, Borg El-Arab City for Scientific Research, Universities and Research District Sector, New Borg El-Arab, Alexandria, Egypt.
Nehal M El-DeebDepartment of Medical Biotechnology, Genetic Engineering and Biotech Institute, Borg El-Arab City for Scientific Research, Universities and Research District Sector, New Borg El-Arab, Alexandria, Egypt.
Mohamed Z HusseinDepartment of Medical Microbiology and Immunology, Tanta University, Tanta, Egypt.
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProbiotic delivery systems are widely used nutraceutical products for the supplementation of natural intestinal flora. These delivery systems vary greatly in the effectiveness to exert health benefits for a patient. This study focuses on providing probiotic living cells with a physical barrier against adverse environmental conditions. MATERIALS AND

methodsMicroencapsulation of the selected lactic acid bacteria (LAB) using chitosan and alginate was performed. Physical examination of the formulated LAB microcapsules was observed using phase contrast inverted microscope and scanning electron microscope (SEM). Finally, the survival of microencapsulated and noncapsulated bacteria was cheeked in the simulated human gastric tract (GT). The potential antimicrobial activity of the most potent microencapsulated LAB strain was in vivo evaluated in rabbit models.

resultsMicroencapsulated L. plantarum, L. acidophilus, and L. bulgaricus DSMZ 20080 were loaded with 1.03 × 10(10) CFU viable bacteria/g, 1.9 × 10(10) CFU viable bacteria/g, and 5.5 × 10(9) CFU viable bacteria/g, respectively. The survival of microencapsulated cells was significantly higher than that of the free cells after exposure to simulated gastric juice (SGJ) at pH 2. Additionally, in simulated small intestine juice (SSJ), larger amounts of the selected LAB cells were found, whereas in simulated colon juice (SCJ), the released LAB reached the maximum counts. In vivo results pointed out that an 8-week supplementation with a triple therapy of a microencapsulated L. plantarum, L. acidophilus, and L. bulgaricus DSMZ 20080 might be able to reduce H. pylori.

conclusionMicroencapsulated probiotics could possibly compete with and downregulate H. pylori infection in humans.

Indexed as

Helicobacter pylori (H. pylori)microcapsuleprobiotics

Identifiers

PMID26929759
PMCPMC4746868
OpenAlexW2338442040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.